The Korea Times
amn_close.png
amn_bl.png
National
  • Politics
  • Foreign Affairs
  • Multicultural Community
  • Defense
  • Environment & Animals
  • Law & Crime
  • Society
  • Health & Science
amn_bl.png
Business
  • Tech
  • Bio
  • Companies
  • World Expo 2030
amn_bl.png
Finance
  • Companies
  • Economy
  • Markets
  • Cryptocurrency
amn_bl.png
Opinion
  • Editorial
  • Columns
  • Thoughts of the Times
  • Cartoon
  • Today in History
  • Blogs
  • Tribune Service
  • Blondie & Garfield
  • Letter to President
  • Letter to the Editor
amn_bl.png
Lifestyle
  • Travel & Food
  • Trends
  • People & Events
  • Books
  • Around Town
  • Fortune Telling
amn_bl.png
Entertainment & Arts
  • K-pop
  • Films
  • Shows & Dramas
  • Music
  • Theater & Others
amn_bl.png
Sports
amn_bl.png
World
  • SCMP
  • Asia
amn_bl.png
Video
  • Korean Storytellers
  • POPKORN
  • Culture
  • People
  • News
amn_bl.png
Photos
  • Photo News
  • Darkroom
amn_NK.png amn_DR.png amn_LK.png amn_LE.png
  • bt_fb_on_2022.svgbt_fb_over_2022.svg
  • bt_twitter_on_2022.svgbt_twitter_over_2022.svg
  • bt_youtube_on_2022.svgbt_youtube_over_2022.svg
  • bt_instagram_on_2022.svgbt_instagram_over_2022.svg
The Korea Times
amn_close.png
amn_bl.png
National
  • Politics
  • Foreign Affairs
  • Multicultural Community
  • Defense
  • Environment & Animals
  • Law & Crime
  • Society
  • Health & Science
amn_bl.png
Business
  • Tech
  • Bio
  • Companies
  • World Expo 2030
amn_bl.png
Finance
  • Companies
  • Economy
  • Markets
  • Cryptocurrency
amn_bl.png
Opinion
  • Editorial
  • Columns
  • Thoughts of the Times
  • Cartoon
  • Today in History
  • Blogs
  • Tribune Service
  • Blondie & Garfield
  • Letter to President
  • Letter to the Editor
amn_bl.png
Lifestyle
  • Travel & Food
  • Trends
  • People & Events
  • Books
  • Around Town
  • Fortune Telling
amn_bl.png
Entertainment & Arts
  • K-pop
  • Films
  • Shows & Dramas
  • Music
  • Theater & Others
amn_bl.png
Sports
amn_bl.png
World
  • SCMP
  • Asia
amn_bl.png
Video
  • Korean Storytellers
  • POPKORN
  • Culture
  • People
  • News
amn_bl.png
Photos
  • Photo News
  • Darkroom
amn_NK.png amn_DR.png amn_LK.png amn_LE.png
  • bt_fb_on_2022.svgbt_fb_over_2022.svg
  • bt_twitter_on_2022.svgbt_twitter_over_2022.svg
  • bt_youtube_on_2022.svgbt_youtube_over_2022.svg
  • bt_instagram_on_2022.svgbt_instagram_over_2022.svg
  • Login
  • Register
  • Login
  • Register
  • The Korea Times
  • search
  • all menu
  • Login
  • Subscribe
  • Photos
  • Video
  • World
  • Sports
  • Opinion
  • Entertainment & Art
  • Lifestyle
  • Finance
  • Business
  • National
  • North Korea
  • 1

    Korea falls to Italy in FIFA U-20 World Cup semifinals

  • 3

    Actor Yoo Ah-in suspected of taking 2 more types of drugs

  • 5

    OpenAI explores investment opportunities in Korean startups: Sam Altman

  • 7

    IPO market regains vigor on bullish KOSPI

  • 9

    China's hallyu restrictions likely to continue unless Seoul-Beijing ties improve

  • 11

    China reaches out to Korean Assembly to counterweigh Yoon's bet on US

  • 13

    INTERVIEWCIX talks about team chemistry, youth theme

  • 15

    SPC bolsters PR activities in US

  • 17

    Hyundai Motor partners with Spider-Man animation to envision future mobility

  • 19

    NCT to hold Korea-Japan stadium tour

  • 2

    Rising minimum wage burdens small biz owners: survey

  • 4

    Jihyo to become 2nd TWICE member to make solo debut

  • 6

    'The Childe': blood-soaked crime thriller with chilling chase scenes

  • 8

    Philippines Day celebrated in Gwangju

  • 10

    Gang Dong-won, Park Jeong-min team up for Joseon-era thriller 'War and Revolt'

  • 12

    S. Korea may see rise in NK defectors as Pyongyang mulls reopening borders

  • 14

    Resurging household loans pose challenge for BOK's rate policy

  • 16

    OpenAI CEO visits Korea as country seeks to encourage AI development

  • 18

    4 Children lost for 40 days in Colombian Amazon found alive

  • 20

    Japanese business leaders pledge to support Busan's Expo bid

Close scrollclosebutton

Close for 24 hours

Open
  • The Korea Times
  • search
  • all menu
  • Login
  • Subscribe
  • Photos
  • Video
  • World
  • Sports
  • Opinion
  • Entertainment & Art
  • Lifestyle
  • Finance
  • Business
  • National
  • North Korea
Opinion
  • Editorial
  • Columns
  • Thoughts of the Times
  • Cartoon
  • Today in History
  • Blogs
  • Tribune Service
  • Blondie & Garfield
  • Letter to President
  • Letter to the Editor
Sun, June 11, 2023 | 08:37
Guest Column
Developing vaccine against COVID-19
Posted : 2020-04-02 18:03
Updated : 2020-04-02 21:55
Print PreviewPrint Preview
Font Size UpFont Size Up
Font Size DownFont Size Down
  • facebook
  • twitter
  • kakaolink
  • whatsapp
  • reddit
  • mailto
  • link


By Jerome H. Kim, MD

Modern vaccine development has been a success, saving 2.5 million lives annually, improving the quality of life, educational attainment and economic growth, and decreasing poverty.

There are few government initiatives that have a higher return on investment than vaccination. For companies that make vaccines the process from the laboratory into the clinic is long, expensive and complex. The process takes, on average, five to 10 years, costs $1 billion, and has a 90 percent failure rate.

COVID-19, however, will not give us the benefit of time. In 12 weeks it has spread to 198 countries, infected over 800,000 and killed more than 40,000.

As social distancing, lockdowns, postponed business meetings, and closed borders grind on, predictions of economic collapse with dramatic societal dislocation are now being made.

Without a vaccine, COVID-19 will continue to pose a threat to countries until roughly 60 percent of the population has been infected. In a country of 50 million, that would mean 30 million infections and 300,000 to 600,000 deaths.

With an effective vaccine, the impact of COVID-19 would effectively be blunted, and life, as it was prior to COVID-19, would be restored ― suggesting the question, "When will there be a vaccine?"

From a vaccine development perspective there are unanswered questions. First, we don't know whether a person can contract COVID-19 twice.

Immunity against a second infection suggests that, for a period of time, immune or defensive responses that defeated the first infection protect against a second ― the inspiration for a vaccine.

But second, we would need to know what those immune responses are ― the presence of proteins that neutralize the virus, virus-specific "killer" cells, or both?

Third, we would like to know that those immune responses protect animals against infection. Finally we don't know whether new vaccine candidates will be safe in humans.

These questions inform and guide vaccine development, and under usual circumstances, we have time to partially answer these questions. These, however, are not usual times.

Vaccine development proceeds in phases. Vaccines are created in a laboratory and tested in animals to see whether they protect against infection. Vaccines are tested to ensure safety in animals, and then enter Phase I testing in humans, where safety and a preliminary vaccine-induced responses are evaluated.

Successful candidates then enter Phase II, where a larger number of individuals in the "target" population are tested to ensure the desired immune responses are present.

Phase III tests a vaccine's ability to protect against infection and disease. Phase III data are pivotal for vaccine approval by a regulatory authorities, the Ministry of Food and Drug Safety in Korea.

Between each phase data are generated, collated and analyzed, and under normal circumstances, the five to -10 year timeframe accommodates this sequential approach.

In a pandemic, however, it is possible to shorten time to development. Phase I and II can be combined and run in an overlapping fashion. Decisions to proceed with subsequent phases might be made on the basis of immune responses after completion of the initial vaccination series.

Hence, we might know whether a vaccine protects against COVID-19 infection in 12 to 18 months. Then the vaccine would need to undergo an expedited regulatory review, and if approved, must be manufactured.

Because preparation for manufacturing can take one to two years, companies often build at risk to ensure rapid manufacturing after approval.

In the rush to a vaccine, we cannot ignore safety. Vaccines are given to the healthy to prevent, not cause, illness. Vaccine trials must be monitored closely by an independent body to ensure that participants suffer no ill effects from vaccination. Safety evaluation should continue for an extended period, to establish short-term and longer-term safety.

We need a vaccine against COVID-19, as a vaccine offers the best hope for a return to life as it was before the pandemic.

We should move quickly to fund and execute COVID-19 vaccine trials, and Korea's strong biotechnology and vaccine manufacturing companies should be at the forefront, working collaboratively to accelerate the development of a vaccine for COVID-19.


The writer is the director general of the International Vaccine Institute (IVI), a Seoul-based international organization devoted to the discovery, development and delivery of vaccines for global public health.


 
wooribank
Top 10 Stories
1Rising minimum wage burdens small biz owners: survey Rising minimum wage burdens small biz owners: survey
2OpenAI explores investment opportunities in Korean startups: Sam Altman OpenAI explores investment opportunities in Korean startups: Sam Altman
3IPO market regains vigor on bullish KOSPI IPO market regains vigor on bullish KOSPI
4China reaches out to Korean Assembly to counterweigh Yoon's bet on US China reaches out to Korean Assembly to counterweigh Yoon's bet on US
5S. Korea may see rise in NK defectors as Pyongyang mulls reopening borders S. Korea may see rise in NK defectors as Pyongyang mulls reopening borders
6Resurging household loans pose challenge for BOK's rate policy Resurging household loans pose challenge for BOK's rate policy
7SPC bolsters PR activities in US SPC bolsters PR activities in US
8Hyundai Motor partners with Spider-Man animation to envision future mobility Hyundai Motor partners with Spider-Man animation to envision future mobility
9Japanese business leaders pledge to support Busan's Expo bid Japanese business leaders pledge to support Busan's Expo bid
10More foreign language tours will be offered for Cheong Wa Dae More foreign language tours will be offered for Cheong Wa Dae
Top 5 Entertainment News
1China's hallyu restrictions likely to continue unless Seoul-Beijing ties improve China's hallyu restrictions likely to continue unless Seoul-Beijing ties improve
2Gang Dong-won, Park Jeong-min team up for Joseon-era thriller 'War and Revolt' Gang Dong-won, Park Jeong-min team up for Joseon-era thriller 'War and Revolt'
3[INTERVIEW] CIX talks about team chemistry, youth theme INTERVIEWCIX talks about team chemistry, youth theme
4Netflix's new original 'Bloodhounds' to deliver cathartic actionNetflix's new original 'Bloodhounds' to deliver cathartic action
5'Leaving Las Vegas' director Mike Figgis puts Korea in spotlight in new film 'Leaving Las Vegas' director Mike Figgis puts Korea in spotlight in new film
DARKROOM
  • Turkey-Syria earthquake

    Turkey-Syria earthquake

  • Nepal plane crash

    Nepal plane crash

  • Brazil capital uprising

    Brazil capital uprising

  • Happy New Year 2023

    Happy New Year 2023

  • World Cup 2022 Final - Argentina vs France

    World Cup 2022 Final - Argentina vs France

CEO & Publisher : Oh Young-jin
Digital News Email : webmaster@koreatimes.co.kr
Tel : 02-724-2114
Online newspaper registration No : 서울,아52844
Date of registration : 2020.02.05
Masthead : The Korea Times
Copyright © koreatimes.co.kr. All rights reserved.
  • About Us
  • Introduction
  • History
  • Contact Us
  • Products & Services
  • Subscribe
  • E-paper
  • RSS Service
  • Content Sales
  • Site Map
  • Policy
  • Code of Ethics
  • Ombudsman
  • Privacy Statement
  • Terms of Service
  • Copyright Policy
  • Family Site
  • Hankook Ilbo
  • Dongwha Group